Article
Immunology
Basudev Paudyal, Adam McNee, Pramila Rijal, B. Veronica Carr, Alejandro Nunez, John McCauley, Rodney S. Daniels, Alain R. Townsend, John A. Hammond, Elma Tchilian
Summary: Prophylactic intravenous administration of specific monoclonal antibodies in pigs showed significant reduction in lung pathology and virus loads, but not consistent reduction in nasal shedding. The effect on lung pathology and virus load is consistent across different doses, suggesting that lower doses may be effective in reducing disease severity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Xiaojie Yu, Christian M. Orr, H. T. Claude Chan, Sonya James, Christine A. Penfold, Jinny Kim, Tatyana Inzhelevskaya, C. Ian Mockridge, Kerry L. Cox, Jonathan W. Essex, Ivo Tews, Martin J. Glennie, Mark S. Cragg
Summary: Low affinity of immunomodulatory antibodies leads to greater activity through increased clustering, resulting in higher immune cell activation, T cell expansion, and antitumor activity. This discovery reveals a new mechanism for enhancing receptor activation across diverse receptor families and sheds light on the mechanism of antibody-mediated receptor signaling. Affinity engineering offers a rational, efficient, and tunable solution for delivering antibody-mediated receptor activity for the treatment of human disease.
Review
Clinical Neurology
Shayan Ali Irfan, Minha Murtaza, Ali Ahmed, Hina Altaf, Abid Anwar Ali, Naqiha Shabbir, Mirza Mehmood Ali Baig
Summary: Analysis of clinical trials assessing the safety and efficacy of Temelimab in patients with Multiple Sclerosis demonstrates that the drug is safe and effective.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Luigi Pontieri, Morten Blinkenberg, Stephan Bramow, Viktoria Papp, Peter Rasmussen, Matthias Kant, Jakob Schaefer, Henrik K. Mathiesen, Michael B. Jensen, Georgi Sirakov, Jonas M. Berg, Tine Kopp, Hanna Joensen, Finn Sellebjerg, Melinda Magyari
Summary: This study evaluated the real-world effectiveness and safety of ocrelizumab treatment for multiple sclerosis (MS) patients in Denmark. The results showed that most patients experienced clinical stabilization and had a favorable adverse event profile consistent with previous clinical trials. Ocrelizumab was well tolerated with minimal side effects reported in only 10% of patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Review
Medicine, General & Internal
Luca Massacesi, Alice Mariottini, Ferdinando Nicoletti
Summary: Evidence of the effectiveness of B-cell-depleting monoclonal antibodies in multiple sclerosis has led to a re-examination of the pathogenesis of the disease. The mechanisms underlying the efficacy of these antibodies likely involve impairing B-cell functions other than antibody secretion and potentially impacting inflammation within the central nervous system. However, further research is needed to understand these mechanisms and the ability of the antibodies to cross the blood-brain barrier.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Hematology
Xavier Leleu, Thomas Martin, Katja Weisel, Fredrik Schjesvold, Shinsuke Iida, Fabio Malavasi, Salomon Manier, Chang-Ki Min, Enrique M. Ocio, Charlotte Pawlyn, Aurore Perrot, Hang Quach, Joshua Richter, Ivan Spicka, Kwee Yong, Paul G. Richardson
Summary: CD38 is a crucial transmembrane glycoprotein involved in the regulation of calcium signaling and immune cell migration to tumor microenvironments. Targeting CD38 with monoclonal antibodies such as isatuximab and daratumumab has shown promising results in the treatment of multiple myeloma patients. These antibodies possess similarities and differences in their mechanisms of action, and have been shown to induce adaptive immune responses and modulate the bone marrow niche. Further research is needed to determine the optimal selection and sequencing of anti-CD38 antibody therapies in relapsed and/or refractory multiple myeloma.
ANNALS OF HEMATOLOGY
(2022)
Review
Clinical Neurology
Kanika Sharma, Sarah Tolaymat, Hongxuyang Yu, Mahmoud Elkhooly, Shruti Jaiswal, Anek Jena, Mihir Kakara, Shitiz Sriwastava
Summary: Progressive multifocal leukoencephalopathy (PML) is a subacute CNS inflammatory disease primarily seen among immunocompromised patients. It is caused by the JC virus (JCV) and can also be associated with monoclonal antibody immunotherapy.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2022)
Article
Hematology
Alex F. Herrera, Joycelynne Palmer, Vikram Adhikarla, Dave Yamauchi, Erasmus K. Poku, James Bading, Paul Yazaki, Savita Dandapani, Matthew Mei, Robert Chen, Thai Cao, Nicole Karras, Pamela McTague, Auayporn Nademanee, Leslie Popplewell, Firoozeh Sahebi, John E. Shively, Jennifer Simpson, D. Lynne Smith, Joo Song, Ricardo Spielberger, Ni-Chun Tsai, Sandra H. Thomas, Stephen J. Forman, David Colcher, Anna M. Wu, Jeffrey Wong, Eileen Smith
Summary: In this study, the addition of 90Y-antiCD25 (aTac) to BEAM AHCT for high-risk relapsed or refractory classical Hodgkin lymphoma (HL) patients was shown to be safe and effective, with favorable outcomes observed in terms of toxicity, engraftment, and overall survival. Further evaluation of this approach in a phase 2 trial is ongoing to assess its efficacy.
Article
Oncology
Thomas G. Martin, Nina Shah, Joshua Richter, David H. Vesole, Sandy W. Wong, Chiung-Yu Huang, Deepu Madduri, Sundar Jagannath, David S. Siegel, Noa Biran, Jeffrey L. Wolf, Samir Parekh, Hearn J. Cho, Pamela Munster, Shambavi Richard, Samira Ziti-Ljajic, Ajai Chari
Summary: This study evaluated the safety and efficacy of Isa and K combination therapy in patients with RRMM. Despite heavily pretreated patients, 70% responded to the treatment, with a median progression-free survival of 10.1 months.
Review
Clinical Neurology
Julia Kraemer, Heinz Wiendl
Summary: The review highlights the importance of safety evaluation, the role of memory B cells in immunopathogenesis, and the relationship between pathophysiology and treatment outcomes when utilizing monoclonal antibodies for the treatment of multiple sclerosis. Understanding these aspects is crucial for optimizing future trial designs and improving therapeutic efficacy.
Article
Biochemistry & Molecular Biology
Nohara Goto, Hiroyuki Suzuki, Tomohiro Tanaka, Teizo Asano, Mika K. Kaneko, Yukinari Kato
Summary: CD44 is a cell surface glycoprotein involved in various cellular functions. The established antibody C(44)Mab-46 is important for cancer diagnosis and therapy by detecting CD44 in different applications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Kara M. Gillmann, J. Sebastian Temme, Samantha Marglous, Claire E. Brown, Jeffrey C. Gildersleeve
Summary: Anti-glycan monoclonal antibodies (mAbs) have diverse applications in human health and basic research, including cancer diagnostics and therapeutics. Despite the limited supply of high-quality anti-glycan mAbs, recent advances have been made in targeting cancer- and infectious disease-associated glycans, providing new opportunities for discovery and development of therapeutic antibodies.
CURRENT OPINION IN CHEMICAL BIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Ryo Ejima, Hiroyuki Suzuki, Tomohiro Tanaka, Teizo Asano, Mika K. Kaneko, Yukinari Kato
Summary: CD44 is a cell surface glycoprotein with isoforms produced by alternative splicing. CD44 variant exon-containing isoforms (CD44v) are overexpressed in carcinomas, and CD44v6 predicts poor prognosis in colorectal cancer patients. CD44v6 plays important roles in CRC adhesion, proliferation, stemness, invasiveness, and chemoresistance. In this study, anti-CD44 monoclonal antibodies (mAbs) were developed and characterized for detecting CD44v6 in various applications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biotechnology & Applied Microbiology
Tereza Gabelic, Barbara Barun, Ivan Adamec, Magdalena Krbot Skoric, Mario Habek
Summary: Traditionally, the management of active relapsing remitting MS involved continuous treatment with disease modifying therapy, while newer approaches include short-term therapy or the use of monoclonal antibodies. The introduction of monoclonal antibodies has revolutionized MS treatment, but the choice of DMT remains a challenge for patients and neurologists.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Chemistry, Multidisciplinary
Zhijue Xu, Zhaoyu Wu, Sheng Huang, Kaichuang Ye, Yihong Jiang, Jianqiang Liu, Junchao Liu, Xinwu Lu, Bo Li
Summary: Immunomodulatory therapy has shown promise in treating cardiovascular diseases, but challenges remain in terms of drug co-delivery and combination therapies. This study developed a multifunctional nanoparticle (RUFI) for treating atherosclerotic cardiovascular disease, which successfully targeted and reduced plaques in mouse models. The study demonstrated the enhanced immunoregulatory effects of combining rapamycin and IL-1Ra through MOF carriers, suggesting potential treatments for atherosclerosis and other inflammatory diseases.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Genetics & Heredity
Sergio E. Baranzini, Pouya Khankhanian, Nikolaos A. Patsopoulos, Michael Li, Jim Stankovich, Chris Cotsapas, Helle Bach Sondergaard, Maria Ban, Nadia Barizzone, Laura Bergamaschi, David Booth, Dorothea Buck, Paola Cavalla, Elisabeth G. Celius, Manuel Comabella, Giancarlo Comi, Alastair Compston, Isabelle Cournu-Rebeix, Sandra D'alfonso, Vincent Damotte, Lennox Din, Benedicte Dubois, Irina Elovaara, Federica Esposito, Bertrand Fontaine, Andre Franke, An Goris, Pierre-Antoine Gourraud, Christiane Graetz, Franca R. Guerini, Lena Guillot-Noel, David Hafler, Hakon Hakonarson, Per Hall, Anders Hamsten, Hanne F. Harbo, Bernhard Hemmer, Jan Hillert, Anu Kemppinen, Ingrid Kockum, Keijo Koivisto, Maim Larsson, Mark Lathrop, Maurizio Leone, Christina M. Lill, Fabio Macciardi, Roland Martin, Vittorio Martinelli, Filippo Martinelli-Boneschi, Jacob L. McCauley, Kjell-Morten Myhr, Paola Naldi, Tomas Olsson, Annette Oturai, Margaret A. Pericak-Vance, Franco Perla, Mauri Reunanen, Janna Saarela, Safa Saker-Delye, Marco Salvetti, Finn Sellebjerg, Per Soelberg Sorensen, Anne Spurkland, Graeme Stewart, Bruce Taylor, Pentti Tienari, Juliane Winkelmann, Frauke Zipp, Adrian J. Ivinson, Jonathan L. Haines, Stephen Sawcer, Philip DeJager, Stephen L. Hauser, Jorge R. Oksenberg
AMERICAN JOURNAL OF HUMAN GENETICS
(2013)
Article
Clinical Neurology
Sven Schippling, Christian Kempf, Fabian Buechele, Ivan Jelcic, Oliver Bozinov, Adriano Bont, Michael Linnebank, Mireia Sospedra, Michael Weller, Herbert Budka, Roland Martin
ANNALS OF NEUROLOGY
(2013)
Article
Clinical Neurology
Malte Mohme, Christian Hotz, Stefan Stevanovic, Thomas Binder, Jar-How Lee, Michal Okoniewski, Thomas Eiermann, Mireia Sospedra, Hans-Georg Rammensee, Roland Martin
Review
Clinical Neurology
Nikolai Pfender, Riccardo Saccardi, Roland Martin
CURRENT TREATMENT OPTIONS IN NEUROLOGY
(2013)
Review
Pharmacology & Pharmacy
Andreas Lutterotti, Roland Martin
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2014)
Article
Genetics & Heredity
J. Jaeger, C. Schulze, S. Roesner, R. Martin
GENES AND IMMUNITY
(2013)
Article
Immunology
Kati Tillack, Matthias Naegele, Cathleen Haueis, Sven Schippling, Klaus-Peter Wandinger, Roland Martin, Mireia Sospedra
JOURNAL OF NEUROIMMUNOLOGY
(2013)
Article
Biochemical Research Methods
Marcel P. Stoop, Vaibhav Singh, Christoph Stingl, Roland Martin, Mohsen Khademi, Tomas Olsson, Rogier Q. Hintzen, Theo M. Luider
JOURNAL OF PROTEOME RESEARCH
(2013)
Article
Virology
Ilijas Jelcic, Lilian Aly, Thomas M. C. Binder, Ivan Jelcic, Silvia Bofill-Mas, Raquel Planas, Victoria Demina, Thomas H. Eiermann, Thomas Weber, Rosina Girones, Mireia Sospedra, Roland Martin
JOURNAL OF VIROLOGY
(2013)
Article
Cell Biology
Andreas Lutterotti, Sara Yousef, Andreas Sputtek, Klarissa H. Stuerner, Jan-Patrick Stellmann, Petra Breiden, Stefanie Reinhardt, Christian Schulze, Maxim Bester, Christoph Heesen, Sven Schippling, Stephen D. Miller, Mireia Sospedra, Roland Martin
SCIENCE TRANSLATIONAL MEDICINE
(2013)
Article
Rheumatology
David A. Martin, Melvin Churchill, Luis Felipe Flores-Suarez, Mario H. Cardiel, Daniel Wallace, Richard Martin, Kristine Phillips, Jeffrey L. Kaine, Hua Dong, David Salinger, Erin Stevens, Chris B. Russell, James B. Chung
ARTHRITIS RESEARCH & THERAPY
(2013)
Editorial Material
Immunology
Roland Martin
Letter
Biophysics
P. Stathopoulos, K. Leger, M. Foege, A. Lutterotti, A. Mueller, U. Schanz, I. Jelcic, R. Martin
BONE MARROW TRANSPLANTATION
(2021)
Article
Biochemistry & Molecular Biology
Nagiua Cuomo-Haymour, Giorgio Bergamini, Giancarlo Russo, Luka Kulic, Irene Knuesel, Roland Martin, Andre Huss, Hayrettin Tumani, Markus Otto, Christopher R. Pryce
Summary: This study investigated the serum extracellular vesicle (EV) microRNAs (miRNAs) in different stages of multiple sclerosis (MS) patients and matched controls, aiming to identify MS stage-specific differential expressed miRNAs and their potential as biomarkers and relevance to the disease. The study found a moderate number of dysregulated serum EV miRNAs in CIS-remission and RRMS-relapse patients, with some miRNAs having potential as biomarkers for patient-control and CIS-RRMS differentiation. In silico analysis identified biological processes related to MS pathophysiology as the mRNA targets of RRMS-relapse-specific EV miRNAs. The findings demonstrate the potential of specific serum EV miRNAs as MS stage-specific biomarkers and provide insights into potential therapeutic targets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Josefine Ruder, Gianna Dinner, Aleksandra Maceski, Ernesto Berenjeno-Correa, Antonia Maria Mueller, Ilijas Jelcic, Jens Kuhle, Roland Martin
Summary: Autologous hematopoietic stem cell transplantation (aHSCT) is an effective treatment for multiple sclerosis (MS), which normalizes pathological processes and enhances beneficial processes. Biomarker analysis of MS patients undergoing aHSCT showed that serum levels of CXCL10, NfL, and GFAP significantly increased one month after transplantation, but returned to normal after one to two years. Levels of GFAP in cerebrospinal fluid (CSF) increased 24 months after aHSCT, indicating sustained astroglia activation. Other CSF markers remained relatively stable.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)